North America Brain Cancer Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, and Others); Cancer Type (Acoustic Neuroma, Astrocytoma, Craniopharyngiomas, Ganglioneuromas, Glioblastoma Multiforme, Meningiomas, Ependymomas, and Others); End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others)
Market Introduction
Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body. Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.
Thus, the increase in prevalence of brain cancer is expected to create a significant demand for brain cancer diagnostics in the coming years, which is further anticipated to drive the brain cancer diagnostics market.
The COVID-19 pandemic has disrupted healthcare systems, leading to concerns about its subsequent impact on non-COVID disease conditions. Cancer diagnosis and treatment are time-sensitive and are likely to be significantly affected by these conditions. The activities of each cancer discipline have been adversely affected by the COVID-19 pandemic. In addition, childhood malignant brain tumors are characterized by rapid growth and require early diagnosis and appropriate treatment. Therefore, delaying or modifying treatment can compromise its effectiveness and reduce patient survival. Flores et al. reported that delayed diagnosis of brain tumors is correlated with a worse prognosis. A prolonged pre-diagnostic symptomatic interval has negative and severe consequences, such as death or serious brain damage following the increase in intracranial pressure. Due to the fear and pressure of SARS CoV2 infection, changes in the decision-making process of children with brain tumors may have a negative impact on their final outcome. Never have multidisciplinary tumor boards serve a crucial role during the current COVID-19 outbreak. All pediatric cases diagnosed with a new brain tumor should be discussed in the multidisciplinary tumor board to determine the best treatment plan for each child.
Get more information on this report :
Market Overview and Dynamics
The Brain cancer diagnostics market in North America is expected to grow from US$ 301.5 million in 2021 to US$ 911.0 million by 2028; it is estimated to grow at a CAGR of 17.1% from 2021 to 2028. The researchers pointed out that the ability of artificial intelligence technology and pathologists to verify each other highlights the need for pathologists to cooperate with artificial intelligence technology to interpret challenging cases and ensure the highest possible diagnostic accuracy. Today, several major cancer centers in the US are using SRH imagers. Both SRH and AI imaging are emerging technologies, so integrating them into healthcare will be challenging. AI technology enables surgeons to identify areas containing tumors or healthy tissue speedily and precisely. Thus, SRH?artificial intelligence is being increasingly used to enhance brain tumor diagnosis during surgery.
Key Market Segments
In terms of diagnostic type, the imaging test segment accounted for the largest share of the North America brain cancer diagnostics market in 2020. In terms of cancer type, the glioblastoma multiforme segment accounted for the largest share of the North America brain cancer diagnostics market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the North America brain cancer diagnostics market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the brain cancer diagnostics market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Thermo Fisher Scientific Inc., Siemens Healthineers A, GE Healthcare, MDxHealth, NantOmics, Biocept, Inc., Koninklijke Philips N.V, Canon Medical Systems, Hitachi, Ltd., and Neusoft Medical Systems.
Reasons to buy report
- To understand the North America Brain cancer diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for North America Brain cancer diagnostics market
- Efficiently plan M&A and partnership deals in North America Brain cancer diagnostics market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America Brain cancer diagnostics market
- Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
North America Brain Cancer Diagnostics Market Segmentation
By Diagnostic Type
- Imaging Test
- MRI
- CT Scan
- PET
- Biopsy
- Molecular Testing
- Lumbar Puncture
- Others
By Cancer Type
- Glioblastoma Multiforme
- Astrocytomas
- Ependymomas
- Others
By End User
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
By Country
- North America
- US
- Canada
- Mexico
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Siemens Healthineers A
- GE Healthcare
- MDxHealth
- NantOmics
- Biocept, Inc.
- Koninklijke Philips N.V
- Canon Medical Systems
- Hitachi, Ltd.
- Neusoft Medical Systems
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Brain Cancer Diagnostics Market – By Diagnostic Type
1.3.2 Brain Cancer Diagnostics Market – By Cancer Type
1.3.3 Brain Cancer Diagnostics Market – By End User
1.3.4 North America Brain Cancer Diagnostics Market – By Country
2. North America Brain Cancer Diagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Brain Cancer Diagnostics Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Brain Cancer Diagnostics Market- North America PEST Analysis
4.3 Expert Opinion
5. North America Brain Cancer Diagnostics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of Brain Cancer
5.1.2 Rise in Number of Cigarette Smokers
5.2 Market Restraints
5.2.1 High Cost of Diagnosis
5.3 Future Trends
5.3.1 Use of Stimulated Raman Histology (SRH)Artificial Intelligence (AI) to Enhance Brain Tumor Diagnosis During Surgery
5.4 Impact Analysis
6. Brain Cancer Diagnostics Market – North America Analysis
6.1 North America Brain Cancer Diagnostics Market Revenue Forecasts and Analysis
7. North America Brain Cancer Diagnostics Market Analysis and Forecasts To 2028 – By Diagnostic Type
7.1 Overview
7.2 Brain Cancer Diagnostics Market Revenue Share, by Diagnostic Type (2020 and 2028)
7.3 Imaging Tests
7.3.1 Overview
7.3.2 Imaging Tests: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.3 MRI
7.3.3.1 Overview
7.3.3.2 MRI: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.4 CT Scan
7.3.4.1 Overview
7.3.4.2 CT Scan: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.3.5 Positron emission tomography (PET)
7.3.5.1 Overview
7.3.5.2 Positron emission tomography (PET): Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Lumbar Puncture
7.4.1 Overview
7.4.2 Lumbar Puncture: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Biopsy
7.5.1 Overview
7.5.2 Biopsy: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Molecular Testing
7.6.1 Overview
7.6.2 Molecular Testing: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Brain Cancer Diagnostics Market Analysis and Forecasts To 2028 – By Cancer Type
8.1 Overview
8.2 Brain Cancer Diagnostics Market Revenue Share, by Cancer Type (2020 and 2028)
8.3 Astrocytomas
8.3.1 Overview
8.3.2 Astrocytomas: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Glioblastoma Multiforme
8.4.1 Overview
8.4.2 Glioblastoma Multiforme: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Ependymomas
8.5.1 Overview
8.5.2 Ependymomas: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9. Brain Cancer Diagnostics Market Analysis – By End user
9.1 Overview
9.2 Brain Cancer Diagnostics Market Revenue Share, by End User (2020 and 2028)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Specialty Clinics
9.4.1 Overview
9.4.2 Specialty Clinics: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Ambulatory Surgical Centers
9.5.1 Overview
9.5.2 Ambulatory Surgical Centers: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10. Brain Cancer Diagnostics Market Revenue and Forecasts to 2028 – Geographical Analysis
10.1 North America: Brain Cancer Diagnostics Market
10.1.1 Overview
10.1.2 North America: Brain Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
10.1.3 US: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.1 US: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.3.2 US Brain Cancer Diagnostics Market, by Diagnostic Type – Revenue and Forecast to 2028 (USD Million)
10.1.3.2.1 US Brain Cancer Diagnostics Market, by Imaging Test – Revenue and Forecast to 2028 (USD Million)
10.1.3.3 US Brain Cancer Diagnostics Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
10.1.3.4 US Brain Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.4 Canada: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.4.1 Canada: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.4.2 Canada Brain Cancer Diagnostics Market, by Diagnostic Type – Revenue and Forecast to 2028 (USD Million)
10.1.4.2.1 Canada Brain Cancer Diagnostics Market, by Imaging Test – Revenue and Forecast to 2028 (USD Million)
10.1.4.3 Canada Brain Cancer Diagnostics Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
10.1.4.4 Canada Brain Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
10.1.5 Mexico: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.5.1 Mexico: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
10.1.5.2 Mexico Brain Cancer Diagnostics Market, by Diagnostic Type – Revenue and Forecast to 2028 (USD Million)
10.1.5.2.1 Mexico Brain Cancer Diagnostics Market, by Imaging Test – Revenue and Forecast to 2028 (USD Million)
10.1.5.3 Mexico Brain Cancer Diagnostics Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
10.1.5.4 Mexico Brain Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
11. Impact Of COVID-19 Pandemic on North America Brain Cancer Diagnostics Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.1 Organic Developments
12.1.1 Overview
12.2 Inorganic Developments
12.2.1 Overview
13. Company Profiles
13.1 THERMO FISHER SCIENTIFIC INC.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Siemens Healthineers AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GE Healthcare
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 MDxHealth
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 NantOmics
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Biocept, Inc.
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Koninklijke Philips N.V.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Canon Medical Systems
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Hitachi, Ltd.
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Neusoft Medical Systems
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About the Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. US Brain Cancer Diagnostics Market, by Diagnostic Type – Revenue and Forecast to 2028 (USD Million)
Table 2. US Brain Cancer Diagnostics Market, by Imaging Test – Revenue and Forecast to 2028 (USD Million)
Table 3. US Brain Cancer Diagnostics Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 4. US Brain Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 5. Canada Brain Cancer Diagnostics Market, by Diagnostic Type - Revenue and Forecast to 2028 (USD Million)
Table 6. Canada Brain Cancer Diagnostics Market, by Imaging Test - Revenue and Forecast to 2028 (USD Million)
Table 7. Canada Brain Cancer Diagnostics Market, by Cancer Type - Revenue and Forecast to 2028 (USD Million)
Table 8. Canada Brain Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 9. Mexico Brain Cancer Diagnostics Market, by Diagnostic Type – Revenue and Forecast to 2028 (USD Million)
Table 10. Mexico Brain Cancer Diagnostics Market, by Imaging Test – Revenue and Forecast to 2028 (USD Million)
Table 11. Mexico Brain Cancer Diagnostics Market, by Cancer Type – Revenue and Forecast to 2028 (USD Million)
Table 12. Mexico Brain Cancer Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 13. Organic Developments in the Brain Cancer Diagnostics Market
Table 14. Inorganic Developments in the Brain Cancer Diagnostics Market
Table 15. Glossary of Terms, Brain Cancer Diagnostics Market
LIST OF FIGURES
Figure 1. Brain Cancer Diagnostics Market Segmentation
Figure 2. North America Brain Cancer Diagnostics Market Overview
Figure 3. Imaging Test Segment Held Largest Share of Diagnostic Type in Brain Cancer Diagnostics Market
Figure 4. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Brain Cancer Diagnostics Market - North America PEST Analysis
Figure 6. Brain Cancer Diagnostics Market Impact Analysis of Driver and Restraints
Figure 7. North America Brain cancer diagnostics Market – Revenue Forecasts and Analysis – 2020- 2028
Figure 8. Brain Cancer Diagnostics Market Revenue Share, by Diagnostic Type (2020 and 2028)
Figure 9. Imaging Tests: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 10. MRI: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. CT Scan: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Positron emission tomography (PET): Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Lumbar Puncture: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Biopsy: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Molecular Testing: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Others: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Brain Cancer Diagnostics Market Revenue Share, by Cancer Type (2020 and 2028)
Figure 18. Astrocytomas: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Glioblastoma Multiforme: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Ependymomas: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Others: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Brain Cancer Diagnostics Market Revenue Share, by End User (2020 and 2028)
Figure 23. Hospitals: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Specialty Clinics: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Ambulatory Surgical Centers: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Others: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. North America: Brain Cancer Diagnostics Market, by Key Country – Revenue (2021) (USD Million)
Figure 28. North America: Brain Cancer Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 29. US: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 30. Canada: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 31. Mexico: Brain Cancer Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 32. Impact of COVID-19 Pandemic in North American Country Markets
Figure 33. Growth Strategies Done by the Companies in the Market, (%)
- Thermo Fisher Scientific Inc.
- Siemens Healthineers A
- GE Healthcare
- MDxHealth
- NantOmics
- Biocept, Inc.
- Koninklijke Philips N.V
- Canon Medical Systems
- Hitachi, Ltd.
- Neusoft Medical Systems
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America brain cancer diagnostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America brain cancer diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the brain cancer diagnostics market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution